173 related articles for article (PubMed ID: 25891385)
1. Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders.
Ong WY; Farooqui T; Kokotos G; Farooqui AA
ACS Chem Neurosci; 2015 Jun; 6(6):814-31. PubMed ID: 25891385
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders.
Farooqui AA; Ong WY; Horrocks LA
Pharmacol Rev; 2006 Sep; 58(3):591-620. PubMed ID: 16968951
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of intracellular phospholipase A2 activity: their neurochemical effects and therapeutical importance for neurological disorders.
Farooqui AA; Litsky ML; Farooqui T; Horrocks LA
Brain Res Bull; 1999 Jun; 49(3):139-53. PubMed ID: 10435777
[TBL] [Abstract][Full Text] [Related]
4. Neuroprotection abilities of cytosolic phospholipase A2 inhibitors in kainic acid-induced neurodegeneration.
Farooqui AA; Ong WY; Horrocks LA
Curr Drug Targets Cardiovasc Haematol Disord; 2004 Mar; 4(1):85-96. PubMed ID: 15058300
[TBL] [Abstract][Full Text] [Related]
5. Phospholipase A2-generated lipid mediators in the brain: the good, the bad, and the ugly.
Farooqui AA; Horrocks LA
Neuroscientist; 2006 Jun; 12(3):245-60. PubMed ID: 16684969
[TBL] [Abstract][Full Text] [Related]
6. A New Generation of Arachidonic Acid Analogues as Potential Neurological Agent Targeting Cytosolic Phospholipase A
Ng CY; Kannan S; Chen YJ; Tan FCK; Ong WY; Go ML; Verma CS; Low CM; Lam Y
Sci Rep; 2017 Oct; 7(1):13683. PubMed ID: 29057981
[TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders.
Phillis JW; Horrocks LA; Farooqui AA
Brain Res Rev; 2006 Sep; 52(2):201-43. PubMed ID: 16647138
[TBL] [Abstract][Full Text] [Related]
8. Control of phospholipase A2 activities for the treatment of inflammatory conditions.
Yedgar S; Cohen Y; Shoseyov D
Biochim Biophys Acta; 2006 Nov; 1761(11):1373-82. PubMed ID: 16978919
[TBL] [Abstract][Full Text] [Related]
9. Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases.
Yarla NS; Bishayee A; Vadlakonda L; Chintala R; Duddukuri GR; Reddanna P; Dowluru KS
Curr Drug Targets; 2016; 17(16):1940-1962. PubMed ID: 26212262
[TBL] [Abstract][Full Text] [Related]
10. Phospholipase A2 and its role in brain tissue.
Farooqui AA; Yang HC; Rosenberger TA; Horrocks LA
J Neurochem; 1997 Sep; 69(3):889-901. PubMed ID: 9282910
[TBL] [Abstract][Full Text] [Related]
11. Structure-based grafting, mutation, and optimization of peptide inhibitors to fit in the active pocket of human secreted phospholipase A2: find new use of old Peptide agents with anti-inflammatory activity.
Zhan C; Li S; Zhong Q; Zhou D
Chem Biol Drug Des; 2015 Apr; 85(4):418-26. PubMed ID: 25187416
[TBL] [Abstract][Full Text] [Related]
12. The role of phospholipase A2 in multiple Sclerosis: A systematic review and meta-analysis.
Trotter A; Anstadt E; Clark RB; Nichols F; Dwivedi A; Aung K; Cervantes JL
Mult Scler Relat Disord; 2019 Jan; 27():206-213. PubMed ID: 30412818
[TBL] [Abstract][Full Text] [Related]
13. Interactions of platinum and ruthenium coordination complexes with pancreatic phospholipase A(2) and phospholipids investigated by MALDI TOF mass spectrometry.
Kamčeva T; Radisavljević M; Vukićević I; Arnhold J; Petković M
Chem Biodivers; 2013 Nov; 10(11):1972-86. PubMed ID: 24243606
[TBL] [Abstract][Full Text] [Related]
14. Modulation of inflammation in brain: a matter of fat.
Farooqui AA; Horrocks LA; Farooqui T
J Neurochem; 2007 May; 101(3):577-99. PubMed ID: 17257165
[TBL] [Abstract][Full Text] [Related]
15. Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases.
Sun GY; Xu J; Jensen MD; Simonyi A
J Lipid Res; 2004 Feb; 45(2):205-13. PubMed ID: 14657205
[TBL] [Abstract][Full Text] [Related]
16. Altered lipid metabolism in brain injury and disorders.
Adibhatla RM; Hatcher JF
Subcell Biochem; 2008; 49():241-68. PubMed ID: 18751914
[TBL] [Abstract][Full Text] [Related]
17. Computer-aided drug design guided by hydrogen/deuterium exchange mass spectrometry: A powerful combination for the development of potent and selective inhibitors of Group VIA calcium-independent phospholipase A
Mouchlis VD; Morisseau C; Hammock BD; Li S; McCammon JA; Dennis EA
Bioorg Med Chem; 2016 Oct; 24(20):4801-4811. PubMed ID: 27320659
[TBL] [Abstract][Full Text] [Related]
18. 2-Oxoamides based on dipeptides as selective calcium-independent phospholipase A
Smyrniotou A; Kokotou MG; Mouchlis VD; Barbayianni E; Kokotos G; Dennis EA; Constantinou-Kokotou V
Bioorg Med Chem; 2017 Feb; 25(3):926-940. PubMed ID: 28034646
[TBL] [Abstract][Full Text] [Related]
19. Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A
Nikolaou A; Kokotou MG; Vasilakaki S; Kokotos G
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Jun; 1864(6):941-956. PubMed ID: 30905350
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of secreted phospholipase A2 suppress the release of PGE2 in renal mesangial cells.
Vasilakaki S; Barbayianni E; Magrioti V; Pastukhov O; Constantinou-Kokotou V; Huwiler A; Kokotos G
Bioorg Med Chem; 2016 Jul; 24(13):3029-3034. PubMed ID: 27234891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
